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A B ST R AC T 
 
 
Despite the improvements in pharmacological and surgical treatments, 
cardiovascular diseases (CVDs) are the number one cause of death 
worldwide. During the last two decades, the search for new therapies has 
been revolutionized with the growing knowledge of stem cell biology. 
Due to their huge differentiation capacity and paracrine effects, 
mesenchymal stem cells (MSCs) are a promising tool for the treatment 
of CVDs. The encouraging outcomes of preclinical studies using MSCs 
as a treatment for diseased myocardium have set the scene for worldwide 
clinical trials. In this review, we overview either complete or ongoing 
clinical trials using MSCs for the therapy of CVDs. In particular, we 
analyze the biological properties of MSCs, elucidate recent clinical 
findings and clinical trial phases of investigation, highlight clinical 
therapeutic effects of MSCs, and discuss challenges towards the clinical 
use of these cells in the therapy of CVDs. 
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The leading cause of mortality and disability 
worldwide are cardiovascular diseases (CVDs), systemic 
circulatory diseases which arise in the field of abnormal 
heart and blood vessels. CVDs accounted for 
approximately 31% of all global deaths, causing 17.8 
million deaths in 2017, mostly in low- and middle-income 
countries [1]. Hypertension, diabetes, hyperlipidemia, 
tobacco use, obesity, a sedentary lifestyle and the harmful 
use of alcohol are the pivotal risk factors for CVDs 
occurrence [2]. In spite of the notable progress in medical 
and surgical therapies, CVDs continue to exhibit high rates 
of morbidity and mortality. Drug therapy problems and 
cardiotoxicity are some of the biggest barriers to 
pharmacotherapy in the treatment of CVDs [3]. Fever, 
postoperative bleeding, stroke, atrial fibrillation, renal 
failure, respiratory distress, cardiogenic shock, and 
myocardial infarction type 5- represent the ordinary 
complications that can occur as a consequence of the 
surgical treatment in patients with CVDs [4,5]. Likewise, 
these therapeutic problems prolong hospital stays and 
increase the overall burden of healthcare expenditures. 
Therefore, a certainty has developed for therapy that it has 
fewer side effects, lower mortality rates, fewer 
complications, as well as better and secure recoveries of 
patients.  
With the recent advances in the field of stem cell 
biology [6], it was suggested that stem cells might be 
exploited to repair damaged cardiac tissue and blood 
vessels. In this review, we overview either complete or 
ongoing clinical trials using MSCs for CVDs conducted 
worldwide. In particular, we analyze the biological 
properties of MSCs, elucidate recent clinical findings  
and clinical trial phases of investigation, highlight the 
clinical therapeutic effects of MSCs, and discuss the 
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challenges towards the clinical use of these cells in the 
therapy of CVDs. 
Discussions 
Mesenchymal stem cells - a new therapeutic strategy 
for cardiovascular diseases 
Mesenchymal stem cells are adult stem cells that can be 
isolated from nearly every tissue type in the adult or infant 
human body [7] such as bone marrow [8], adipose tissue 
[9], peripheral blood [10], synovium, and synovial fluid 
[11], menstrual blood and endometrium [12], skin [13], the 
dental pulp [14], umbilical cord blood [15], Wharton’s jelly 
[16], amniotic fluid and placenta [17], breast milk [18], and 
urine [19] (Figure 1). Usually, MSCs are plastic-adherent, 
fibroblast-like cells that are qualified to differentiate to 
osteoblasts, chondroblasts, and adipocytes in vitro [20]. 
MSCs are able to transdifferentiate into non-mesodermal 
cells such as neurons or astrocytes, hepatocytes, and 
pancreatic cells under specified culture conditions [21]. 
Due to the absence of an MSC-specific marker, the 
Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy proposed a 
minimum number of criteria for the phenotypic 
characterization of human MSCs [22]. MSCs are positive 
for CD105, CD73, and CD90 and characterized by the lack 
of expression CD45, CD34, CD14, CD11b, CD79 alpha or 
CD19, and HLA-DR surface molecules [22]. 
A tremendous number of animal models that resemble 
the pathology of CVDs in humans have demonstrated not 
only the therapeutic efficacy of culture-expanded MSCs, 
but also their mechanism of action that may be of relevance 
to the future widespread clinical use of MSCs [23-30]. 
MSCs represent a cellular source for cardiovascular repair 
since they are able to differentiate into cardiomyocytes 
(CMs) [31-33], endothelial cells (ECs) [34-36], and 
smooth muscle cells (SMCs) [36-38] (Figure 1). However, 
very few MSCs are found engrafted at the site of injury 
linked to the degree of functional recovery [7,21]. Thus, 
the vast majority of recently published studies revealed that 
the beneficial effects and utilization of MSCs in CVDs will 
be also based on their ability to produce a wide range of 
cytokines, chemokines, and growth factors [39] that 
resolve inflammation [24], inhibit apoptosis [26,27] and 
fibrosis [26,40], promote angiogenesis [25,29,40-50], and 
induce endogenous cardiomyocyte regeneration [43-45] 
(Figure 1).  
MSCs attenuate cardiac injury through the production 
of several pro-angiogenic factors such as the placental 
growth factor (PGF), vascular endothelial growth factor 
(VEGF), insulin-like growth factor (IGF-1), and basic 
fibroblast growth factor (bFGF), which facilitate tissue 
regeneration by inducing the proliferation of ECs and by 
promoting neovascularization [25,26,29,40-42,46]. In cell-
to-cell contact and through the production of soluble 
mediators, MSCs can alter the function of all immune cells 
that have a key role in the pathogenesis of CVDs [47,48]. 
MSCs regulate the proliferation, activation, and effector 
function of T lymphocytes, professional antigen-
presenting cells (dendritic cells, macrophages, B 
lymphocytes), NK cells, and NKT cells [48,49]. Thus, the 
improvement of a wide range of cardiac functions 
(increased EF, decreased in scar tissue, reversed 
remodeling, ameliorated contractility, augmented heart 
perfusion, and improved blood vessel density) [30,41,50-
52], indicates the possible use of MSCs in the therapy of 
CVDs. Over the past few years, MSCs were used in a broad 
range of clinical trials exploring the therapeutic effects of 
MSCs in the treatment of coronary artery disease, heart 
failure, and cardiomyopathy (Table 1), as well as 
peripheral artery disease and stroke (Table 2) and their 
findings, were analyzed in this review. 
 
Figure 1. The main mechanisms responsible for MSC- 
based treatment of CVDs. Transplanted MSCs can 
contribute to cardiovascular repair and regeneration by 
forming endothelial cells (ECs), smooth muscle cells 
(SMCs) and cardiomyocytes (CMs) (differentiation). 
Additionally, MSCs produce a broad range of cytokines, 
chemokines, and growth factors that resolve 
inflammation, inhibit apoptosis and fibrosis, promote 
angiogenesis, and induce endogenous cardiomyocyte 
regeneration. 
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MSC-based therapy of coronary artery disease 
One study showed that one month after ST-elevation 
MI (STEMI), the intracoronary infusion of autologous 
bone marrow-derived MSCs (BM-MSCs) provided a 
modest improvement in the left ventricular ejection 
fraction (LVEF) at six-months follow-up by single-photon 
emission computed tomography [51]. It is also important 
to notice that there was no treatment-related toxicity during 
the administration of MSCs, and no serious cardiovascular 
complications throughout the follow-up [51]. For the 
reason that cell therapy is not possible at an early phase of 
remodeling, growing evidence recommends that the 
prevention of LV remodeling by MSCs transplantation 
throughout the late dilation phase is practical [53]. As a 
proper technique for supplementing primary percutaneous 
coronary intervention (PCI), several research groups 
investigated intracoronary transplantation of autologous 
BM-MSCs [53,54].  
In patients with acute anterior wall MI, they found that 
the administration of autologous BM-MSC at one month 
after PCI is tolerable and safe with a significant 
improvement in LVEF one month and four months after 
the stem cell treatment [54]. Serial cardiac 
echocardiographic monitoring displayed that the 
improvement of the cardiac function was kept nearly six 
months after the procedure [53]. At the 16–36- month 
follow-up, the implanted cardioverter defibrillators failed 
to discover sustained or non-sustained ventricular 
arrhythmia in any patient with previous anteroseptal MI 
who underwent intracoronary transplantation of 
autologous BM-MSCs [55]. MSCs may be used as an 
allogeneic graft for the treatment of CVDs, due to the lack 
of various major histocompatibility complex and 
costimulatory cell-surface antigens [56,57].  
In a randomized, double-blind, placebo-controlled 
study, Hare and co. showed that the intravenous 
administration of allogeneic BM-MSCs (0.5, 1.6, and 
5.0×106 MSCs/kg body weight) is well-tolerated, safe, 
and effective in patients after acute anterior MI [58]. In 
the same study, they showed that LVEF, forcible 
expiratory volume and global symptom score were 
significantly improved, while the incidence of arrhythmia 
was reduced in MSC-treated compared to placebo-treated 
post-infarction subjects [58]. In a double-blind, 
randomized controlled trial of Gao and co., it was 
elucidated that the intracoronary application of WJMSCs 
in patients with acute STEMI significantly increased 
myocardial viability, perfusion within the infarcted 
territory, as well as the global LVEF [52]. WJMSC 
infusion averted post-infarct LV adverse remodeling, as 
evidenced by the modifications in the LV end-systolic 
volumes (LVESV) and end-diastolic volumes (LVEDV) 
at 18 months [52] (Table 1). 
MSCs as novel therapeutic agents in the treatment of 
heart failure  
It was demonstrated that intra-myocardial injections of 
autologous BM-MSCs were safe and improved the 
myocardial function in patients with ischemic HF, 
compared to placebo in terms of LVEF, stroke volume, 
myocardial mass, and cardiac output [59,60]. The 
administration of BM-MSCs, as evidenced by progressive 
decreases in both LVEDV and LVESV, led to reverse LV 
remodeling, indicating an improved outcome in patients 
with HF [59,60]. 
In patients with ischemic or non-ischemic HF, Perin and 
co. evaluated the feasibility and safety of different doses (25, 
75, or 150 million cells) of immune-selected allogeneic 
mesenchymal precursors cells (MPCs [61]. They found that 
the transendocardial route of delivery for MPCs therapy was 
safe and well-tolerated without clinically symptomatic 
immune responses [61]. The highest MPCs dose diminished 
the adverse cardiac events and reversed certain parameters 
of cardiac remodeling in HF patients [61]. Nevertheless, 
further studies are needed to explore the relationship 
between the number of intramyocardial injections, the 
number of stem cells and the volume administered, and their 
impact on the observed reverse remodeling outcome. 
Kastrup and co. formed a centralized production of an 
allogeneic Cardiology Stem Cell Centre adipose-derived 
stromal cell (CSCC_ASC) product from healthy donors that 
delivered directly to the myocardium into the border area of 
infarcted tissue and showed safety, feasibility, and a 
tendency toward clinical efficacy in ten patients with 
ischemic heart disease and ischemic HF [62]. It is important 
to notice that none of the patients had any clinical symptoms 
or changes in biochemical parameters or inflammatory signs 
implying immunization. With the aim of assessing changes 
in parameters such as LVEDV, LVEF, stroke volume, 
myocardial mass, cardiac output, and change in clinical 
symptoms in ischemic HF patients treated with CSCC_ASC, 
a double-blind, placebo-controlled, multicenter study is 
currently in phase II [63]. The umbilical cord-derived MSCs 
(UC-MSCs) are easily attainable stem cells and can 
differentiate into cardiomyocyte-like and ECs in vitro, and 
also exert paracrine effects that enhance vascular 
regeneration and cardiomyocyte protection. Due to concerns 
about the safety of donor cell entrapment in the pulmonary 
circulation and whether they will achieve their therapeutic 
effect in a context of low cardiac engraftment, there is 
limited experience on intravenous administration of MSCs 
in patients with CVDs [64]. The intravenous delivery of UC-
MSCs seems safe and efficient in patients with chronic 
stable HF [64]. UC-MSC–treated group exhibited 
significant improvements in the ventricular systolic 
function, New York Heart Association functional 
classification (NYHA Classification), and quality of life 
indices [64] (Table 1). 
  




Table 1. Clinical trials using MSCs to treat cardiac diseases  













AMI auto-BM-MSCs IC 48 000- 60 000 6 Yes 53 
AMI allo-BM-MSCs IV 0.5, 1.6 or 5/kg 6 No 58 
AMI allo-WJMSCs IC 6 18 Yes 52 
AMI auto-BM-MSCs IC 72 6 Yes 51 
AMI auto-BM-MSCs IC 72 4 and 12 Yes 54 
IHF auto-BM-MSCs IM 53.8 6 Yes 59 
HHF auto-BM-MSCs IM 600 13 Yes 60 
IHD and 
IHF 
allo-ASCs IM 100 6 Yes 62 
ICM or 
NICM 




IM 100 6 Yes 63 










No control (yes) 
No control 
57 
ICM auto-BM-MSCs IM 200 12 No 66 
ICM auto-BM-MSCs IM 20 or 200 18 No control 67 
DCM auto-BM-MSCs IC 490 12 Yes 69 




IM 20, 100 or 200 13 No control 68 
Abbreviations: AMI- acute myocardial infarction; IHF- ischemic heart failure; ICM- ischemic cardiomyopathy; 
NICM- non-ischemic cardiomyopathy;  DCM- dilated cardiomyopathy; IHD- ischemic heart disease; IHF- 
ischemic heart failure; auto- autologous; BM-MSCs- bone marrow-derived mesenchymal stem/stromal cells; 
allo- allogeneic; WJMSCs- Wharton's jelly-derived mesenchymal stem cells; ASCs- adipose derived stromal 
cells; MPCs- mesenchymal precursor cells, CSCC_ASC- Cardiology Stem Cell Centre adipose-derived stromal 
cell; AT- adipose tissue derived; UC-MSC- Umbilical cord–derived mesenchymal stem cells; IC- intracoronary 
injection; IV- intravenous injection; IM- intramyocardial injection. 
MSCs as new agents in cell-based therapy of 
cardiomyopathy  
Progressive disorders most often end with heart 
transplants and they are known as ischemic cardiomyopathy 
(ICM) and dilated cardiomyopathy (DCM). Given the fact 
that MSCs secrete numerous paracrine factors that attenuate 
these mechanisms and possess immunomodulatory 
properties, they are a promising therapy for both forms of 
cardiomyopathy [65]. 
For patients with chronic ICM and LV dysfunction, it 
was shown that transendocardial and intramyocardial 
injections of autologous MSCs were safe [66,67]. MSCs 
improved the cardiac structure and function through 
several mechanisms such as reducing fibrosis and 
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promoting neoangiogenesis and neomyogenesis [67]. 
Increased viable myocardial mass and decreased scar size 
suggested a true MSC-mediated myocardial regeneration 
[66,67]. Moreover, an improvement in clinical outcomes 
such as a 6-minute walk test and Minnesota Living with 
Heart Failure Questionnaire in cardiac patients receiving 
MSCs therapy was associated with increased LVEF 
[66,67]. 
Hare and co. conducted a randomized comparison on 
the safety and efficacy of allogeneic versus autologous 
BM-MSCs in patients with cardiomyopathy [57,68]. In 
both sorts of cardiomyopathies- ICM and DCM, 
transendocardial injections of allogeneic and autologous 
MSCs were equally safe without serious adverse events or 
immunological reactions, additionally propounding that 
allogeneic MSCs are characteristically immunomodulatory 
[57,68]. MSCs therapy improved the functional capacity 
and the quality of life in both clinical entities [57,68]. 
Several lines of evidence suggested clinically meaningful 
efficacy and immunosuppressive capacity of allogeneic 
MSCs compared to autologous MSCs in DCM patients 
[68]. Through endocrine or paracrine effects, which might 
promote neovascularization, inhibit cardiomyocyte 
apoptosis and enhance cardiac repair it is possible to 
explain the sustained improvement in LVEF, NYHA class, 
and myocardial perfusion [69]. Interestingly, ventricular 
remodeling was reversed by both of MSCs- autologous and 
allogeneic with inverse dose-response [57]. Specifically, in 
a group of patients with ICM who received lower-doses of 
MSCs (20 million cells) compared to the group that 
received 200 million cells, it was found that the first group 
of patients had significantly greater LVEF, improvement 
in LVESV, and a reduction in scar size [57]. Due to 
discrepant and conflicting results, Florea et al. evaluated 
the relationship between MSCs dose and clinical benefit in 
patients with ICM [70]. Although both cell doses (20 or 
100 million allogeneic BM-MSCs) reduced the scar size, 
merely the higher dose of MSCs increased EF [70].   
MSC-mediated modulation of peripheral artery disease 
Peripheral arterial disease (PAD) is a common 
complication of atherosclerosis. One of the most severe 
forms of PAD is critical limb ischemia (CLI) which is 
characterized by rest pain, ischemic ulceration, or gangrene 
with or without tissue damage [71]. MSCs may improve 
the consequences of CLI due to their combining potential 
for inducing angiogenesis and the immunomodulatory 
environment in situ (Table 2).  
During the 24-week follow-up period, the autologous 
transplantation of BM-MSCs in diabetic patients with CLI 
and foot ulcers was well tolerated and effective with 
respect to a few hemodynamic and clinical parameters 
[72]. In the same study, it was displayed that magnetic 
resonance angiography scores, Ankle-Brachial Pressure 
Index (ABPI), and transcutaneous oxygen pressure before 
and after the infusion of the cells revealed the increased 
blood flow, presumable interceded by collateral vessel 
development [72]. The clinical improvement was verified 
by ulcer healing rate and painless walking [72]. Posterior 
to intramuscular administration of allogeneic BM-MSCs (2 
million cells/kg) in patients with CLI, significantly 
improved ankle pressure and ABPI were noticed [73]. 
There was no utility in the treatment with BM-MSCs for 
patients with impending amputation [73]. Due to the higher 
frequency of obtaining the unit of tissue per volume, and 
larger angiogenic potential compared to BM-MSCs, 
adipose tissue-derived MSCs (AT-MSCs) have been 
proposed as feasible approaches for the treatment of 
disorders related to limb ischemia [74]. A CellDREAM 
trial displayed that the intramuscular injection of AT-
MSCs into the ischemic leg of patients with CLI improved 
ulcer evolution and wound healing and increased 
transcutaneous oxygen pressure without any further 
complications [74]. Besides, a meta-analysis on the usage 
of stem cell therapy in CLI certified the benefits observed 
in single studies [75]. 
Mesenchymal stem cells therapy in stroke 
By using the conventional definition of stroke, it can be 
understood as the abrupt beginning of the loss of focal 
neurological function due to infarction or hemorrhage in 
the critical segment of the brain, retina, or spinal cord [76]. 
It is also important to note that stroke is the leading cause 
of major disabilities and the second leading cause of death 
worldwide [77]. Many studies revealed that the application 
of MSCs in ischemic stroke is secure [78-82], and effective 
throughout long-term tracking [78-80,82] (Table 2). In the 
first intracerebral stem cell transplantation study, 18 
patients with chronic stroke received a single dose of 
modified BM-MSCs (SB623) (2.5×106, 5.0×106, or 
10×106) and demonstrated a significant improvement in the 
neurological function measured by means of the European 
Stroke Scale (ESS), the National Institutes of Health Stroke 
Scale (NIHSS), Fugl-Meyer (F-M) total score, and Fugl-
Meyer (F-M) motor function total score at 12 months after 
the treatment [78].  
Lee and co. elucidated that the intravenous application of 
5×107 autologous MSCs to patients with ischemic stroke 
improved the clinical parameters that were correlated with 
the plasma stromal cell-derived factor-1 alpha level at the 
time of MSC treatment as well as significantly reduced the 
mortality rate compared to a control group [82]. Levy and 
co. showed that the intravenous injection of allogeneic 
MSCs (the same as the autologous transplantation of MSCs) 
in patients with chronic stroke did not cause any adverse 
events [80]. MSCs in each dose (0.5, 1.0, and 1.5 million 
cells/kg body weight) were safe and related to the functional 
recovery [80]. 
  





















IM 930 4 
significant improvements 
in limb perfusion 
regarding painless 
walking time, ABI, TcO2, 
and MRA, and promotion 





IM 2/kg 24 
improvement in rest pain, 
significant increase in 
ABPI and ankle pressure, 






IM 100 6 
TcO2 increased, 













in neurological function 
in ESS, NIHSS, F-M 
total score and F-M 


















IV 50 60 
clinical improvement 
according to mRS, and 
level of SDF‐1α 
82 
Abbreviations: CLI- critical limb ischemia; Auto- autologous; Allo- allogeneic; BM-MSCs- bone marrow-
derived mesenchymal stem cells; AT-MSCs- adipose tissue-derived mesenchymal stem cells; IM- 
intramuscular injection; IV- intravenous injection; ABI- ankle-brachial index; TcO2- transcutaneous oxygen 
pressure; MRA- magnetic resonance angiography; ABPI- Ankle Brachial Pressure Index; ESS- European 
Stroke Scale; NIHSS- National Institutes of Health Stroke Scale; F-M- Fugl-Meyer total score; mRS- modified 
Rankin Scale; SDF ‐ 1α- Stromal Derived Factor 1-α; BI- Bartal score index; MMSE- Mini-Mental Status 
Exam; GDSS- Geriatric Depression Scale scores. 
Conclusions 
Mesenchymal stem cells are considered the new 
therapeutic agents in the treatment of CVDs, on the 
grounds of their differentiation abilities and paracrine 
effects. The results obtained in a large number of clinical 
trials suggest that the local as well as the systemic 
application of autologous or allogeneic MSCs is a 
beneficial therapeutic approach for CVDs. Although these 
studies are paving the way for the development of MSC-
based regenerative therapies for structural and functional 
disorders of the myocardium and blood vessels, the optimal 
origin and the number of transplanted MSCs as well as the 
route of their application should be clearly defined and 
uniformed in such a way so as to increase the 
reproducibility and the consistency of the data. Moreover, 
safety issues regarding MSCs-based therapy are still a 
matter of debate. The primary concern is the unwanted 
differentiation of the transplanted MSCs and their potential 
to suppress the anti-tumor immune response and generate 
new blood vessels that may promote tumor growth and 
metastasis [83-86], although some studies displayed 
opposite results [86]. Therefore, new clinical studies should 
be focused on the continuous monitoring and the long-term 
follow-up of MSC-treated patients in order to determine the 
possible side effects of MSC-based therapy of CVDs.  
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